SEC Form 4 · accession 0001209191-19-002033
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Mosbrooker
Officer — SVP, Chief Commercial Officer
Period of report
Jan 3, 2019
Accepted (ET)
Jan 4, 2019 · 4:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 3, 2018 | A | 31,500 | $0.00 | A | 31,800 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $22.01 | Jan 3, 2019 | A | 87,750 | A | — | Jan 3, 2029 | Common Stock | 87,750 | 87,750 | D |
Explanation of responses
- F1The reported transaction involved the reporting person's receipt of a grant of 31,500 restricted stock units ("RSUs") pursuant to the issuer's 2018 Equity Inducement Plan. Each RSU represents a contingent right to receive one (1) share of the issuer's common stock upon settlement for no consideration. The RSUs will vest as to 25% of the total shares on January 3, 2020, and an additional 6.25% of the total shares will vest quarterly thereafter on March 5, June 5, September 5 and December 5, with 100% of the total shares vested and exercisable on December 5, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.
- F2The option will vest as to 25% of the total shares on January 3, 2020, and an additional 2.0833% of the total shares will vest monthly thereafter beginning February 3, 2020, with 100% of the total shares vested and exercisable on January 3, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.